Amodiaquine plus sulphadoxine-pyrimethamine combination — Competitive Intelligence Brief

Amodiaquine plus sulphadoxine-pyrimethamine combination (Amodiaquine plus sulphadoxine-pyrimethamine combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation Infectious Disease Small molecule

Target snapshot

Amodiaquine plus sulphadoxine-pyrimethamine combination (Amodiaquine plus sulphadoxine-pyrimethamine combination) — Centre for Global Health Research, Ghana. This combination inhibits parasite DNA synthesis and folate metabolism through two complementary antimalarial agents that work synergistically against Plasmodium parasites.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amodiaquine plus sulphadoxine-pyrimethamine combination TARGET	Amodiaquine plus sulphadoxine-pyrimethamine combination	Centre for Global Health Research, Ghana	marketed	Antimalarial combination	Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation
Atovaquone Proguanil and Artesunate Pyronaridine	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
amodiaquine-artesunate versus amodiaquine	amodiaquine-artesunate versus amodiaquine	Charite University, Berlin, Germany	marketed	Antimalarial combination	Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge
artesunate and mefloquine	artesunate and mefloquine	Mepha Ltd.	marketed	Antimalarial combination	Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)
Artesunate-amodiaquine fixed-dose combination	Artesunate-amodiaquine fixed-dose combination	Epicentre	marketed	Antimalarial combination	Plasmodium falciparum (multiple parasite targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class